Recent advances in primary cutaneous B-cell lymphomas

Current Opinion in Oncology

Volumn 26, Issue 2, 2014, Pages 230-236

  Vermeer, Maarten H ^a   Willemze, Rein ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Classification; Cutaneous B cell lymphomas; Therapy

Indexed keywords

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA, B-CELL; NEOPLASM STAGING; NF-KAPPA B; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 84894045225     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000060     Document Type: Review

References (46)

1. Smith BD, Smith GL, Cooper DL, Wilson LD. The cutaneous B-cell lymphoma prognostic index: A novel prognostic index derived from a population-based registry. J Clin Oncol 2005; 23:3390-3395
2. Kodama K, Massone C, Chott A, et al. Primary cutaneous large B-cell lymphomas: Clinicopathologic features, classification, and prognostic factors in a large series of patients. Blood 2005; 106:2491-2497
3. Zinzani PL, Quaglino P, Pimpinelli N, et al., Italian Study Group for Cutaneous Lymphomas. Prognostic factors in primary cutaneous B-cell lymphoma: The Italian Study Group for Cutaneous Lymphomas. J Clin Oncol 2006; 24: 1376-1382
4. Senff NJ, Hoefnagel JJ, Jansen PM, et al. Reclassification of 300 primary cutaneous B-cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: Comparison with previous classifications and identification of prognostic markers. J Clin Oncol 2007; 25:1581-1587
5. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105:3768-3785
6. Hallermann C, Kaune KM, Gesk S, et al. Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas. J Invest Dermatol 2004; 123:213-219
7. Bradford PT, Devesa SS, Anderson WF, Toro Jr. Cutaneous lymphoma incidence patterns in the United States: A population-based study of 3884 cases. Blood 2009; 113:5064-5073
8. Hamilton SN, Wai ES, Tan K, et al. Treatment and outcomes in patients with primary cutaneous b-cell lymphoma: The BC Cancer Agency Experience. Int J Radiat Oncol Biol Phys 2013; 87:719-725
9. Hallermann C, Niermann C, Fischer RJ, Schulze HJ. Survival data for 299 patients with primary cutaneous lymphomas: A monocentre study. Acta Derm Venereol 2011; 91:521-525
10. Lee JH, Lee JH, Yoo DS, et al. Characteristics of primary cutaneous lymphoma according to WHO-EORTC classification in Korea. Clin Exp Dermatol 2013; 38:457-463
11. Fujita A, Hamada T, Iwatsuki K. Retrospective analysis of 133 patients with cutaneous lymphomas from a single Japanese medical center between 1995 and 2008. J Dermatol 2011; 38:524-530
12. Kim YH, Willemze R, Pimpinelli N, et al., ISCL and the EORTC. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110:479-484
13. Senff NJ, Kluin-Nelemans HC, Willemze R. Results of bone marrow examination in 275 patients with histological features that suggest an indolent type of cutaneous B-cell lymphoma. Br J Haematol 2008; 142:52-56
14. Senff NJ, Willemze R. The applicability and prognostic value of the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sé zary syndrome: Results on a large cohort of primary cutaneous B-cell lymphomas and comparison with the system used by the Dutch Cutaneous Lymphoma Group. Br J Dermatol 2007; 157:1205-1211
15. Golling P, Cozzio A, Dummer R, et al. Primary cutaneous B-cell lymphomas: Clinicopathological, prognostic and therapeutic characterisation of 54 cases according to the WHO-EORTC classification and the ISCL/EORTC TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome. Leuk Lymphoma 2008; 49:1094-1103
16. Senff NJ, Noordijk EM, Kim YH, et al., European Organization for Research and Treatment of Cancer; International Society for Cutaneous Lymphoma. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 2008; 112:1600-1609
17. Rijlaarsdam U, Bakels V, van Oostveen JW, et al. Demonstration of clonal immunoglobulin gene rearrangements in cutaneous B-cell lymphomas and pseudo-B-cell lymphomas: Differential diagnostic and pathogenetic aspects. J Invest Dermatol 1992; 99:749-754
18. Edinger JT, Kant JA, Swerdlow SH. Cutaneous marginal zone lymphomas have distinctive features and include 2 subsets. Am J Surg Pathol 2010; 34:1830-1841
19. van Maldegem F, van Dijk R, Wormhoudt TA, et al. The majority of cutaneous marginal zone B-cell lymphomas expresses class-switched immunoglobulins and develops in a T-helper type 2 inflammatory environment. Blood 2008; 112:3355-3361
20. Rijlaarsdam JU, van der Putte SC, Berti E, et al. Cutaneous immunocytomas: A clinicopathologic study of 26 cases. Histopathology 1993; 23:117-125
21. Brenner I, Roth S, Puppe B, et al. Primary cutaneous marginal zone lymphomas with plasmacytic differentiation show frequent IgG4 expression. Mod Pathol 2013; 26:1568-1576
22. Senff NJ, Hoefnagel JJ, Neelis KJ, et al., Dutch Cutaneous Lymphoma Group. Results of radiotherapy in 153 primary cutaneous B-cell lymphomas classified according to the WHO-EORTC classification. Arch Dermatol 2007; 143: 1520-1526
23. Hoefnagel JJ, Vermeer MH, Jansen PM, et al. Primary cutaneous marginal zone B-cell lymphoma: Clinical and therapeutic features in 50 cases. Arch Dermatol 2005; 141:1139-1145
24. Gerami P, Wickless SC, Rosen S, et al. Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sé zary syndrome in primary cutaneous marginal zone lymphoma. J Am Acad Dermatol 2008; 59:245-254
25. Servitje O, Muniesa C, Benavente Y, et al. Primary cutaneous marginal zone B-cell lymphoma: Response to treatment and disease-free survival in a series of 137 patients. J Am Acad Dermatol 2013; 69:357-365
26. Hoefnagel JJ, Dijkman R, Basso K, et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood 2005; 105:3671-3678
27. Dijkman R, Tensen CP, Jordanova ES, et al. Array-based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B-cell lymphoma. J Clin Oncol 2006; 24:296-305
28. Neelis KJ, Schimmel EC, Vermeer MH, et al. Low-dose palliative radiotherapy for cutaneous B-And T-cell lymphomas. Int J Radiat Oncol Biol Phys 2009; 74:154-158
29. Morales AV, Advani R, Horwitz SM, et al. Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab. J Am Acad Dermatol 2008; 59:953-957
30. Valencak J, Weihsengruber F, Rappersberger K, et al. Rituximab monotherapy for primary cutaneous B-cell lymphoma: Response and follow-up in 16 patients. Ann Oncol 2009; 20:326-330
31. Qué reux G, Brocard A, Peuvrel L, et al. Systemic rituximab in multifocal primary cutaneous follicle centre lymphoma. Acta Derm Venereol 2011; 91:562-567
32. Brandenburg A, Humme D, Terhorst D, et al. Long-Term outcome of intravenous therapy with rituximab in patients with primary cutaneous B-cell lymphomas. Br J Dermatol 2013; 169:1126-1132
33. Peñate Y, Hernández-Machín B, Pé rez-Méndez LI, et al. Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: An epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma. Br J Dermatol 2012; 167:174-179
34. Koens L, Vermeer MH, Willemze R, Jansen PM. IgM expression on paraffin sections distinguishes primary cutaneous large B-cell lymphoma, leg type from primary cutaneous follicle center lymphoma.AmJ Surg Pathol 2010; 34:1043-1048
35. Dijkman R, Tensen CP, Buettner M, et al. Primary cutaneous follicle center lymphoma and primary cutaneous large B-cell lymphoma, leg type, are both targeted by aberrant somatic hypermutation but demonstrate differential expression of AID. Blood 2006; 107:4926-4929
36. Pham-Ledard A, Prochazkova-Carlotti M, Andrique L, et al. Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma. Mod Pathol 2013. [Epub ahead of print
37. Senff NJ, Zoutman WH, Vermeer MH, et al. Fine-mapping chromosomal loss at 9p21: Correlation with prognosis in primary cutaneous diffuse large B-cell lymphoma, leg type. J Invest Dermatol 2009; 129:1149-1155
38. Grange F, Beylot-Barry M, Courville P, et al. Primary cutaneous diffuse large B-cell lymphoma, leg type: Clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol 2007; 143:1144-1150
39. Grange F, Maubec E, Bagot M, et al. Treatment of cutaneous B-cell lymphoma, leg type, with age-Adapted combinations of chemotherapies and rituximab. Arch Dermatol 2009; 145:329-330
40. Fink-Puches R, Wolf IH, Zalaudek I, et al. Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol 2005; 52:847-853
41. Gellrich S, Muche JM, Wilks A, et al. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas: An applicational observation. Br J Dermatol 2005; 153:167-173
42. Heinzerling LM, Urbanek M, Funk JO, et al. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer 2000; 89:1835-1844
43. Pham-Ledard A, Cappellen D, Martinez F, et al. MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type. J Invest Dermatol 2012; 132:2118-2120
44. Koens L, Zoutman WH, Ngarmlertsirichai P, et al. Nuclear factor-kB pathwayactivating gene aberrancies in primary cutaneous large B-cell lymphoma, leg type. J Invest Dermatol 2014; 134:290-292
45. Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011; 470:115-119
46. Lim KH, Yang Y, Staudt LM. Pathogenetic importance and therapeutic implications of NF-kB in lymphoid malignancies. Immunol Rev 2012; 246: 359-378